Last updated: February 13, 2026
What Is NDC 70677-1081?
NDC 70677-1081 refers to Lymphazurin (isosulfan blue), a dye used primarily in sentinel lymph node biopsies for breast cancer and melanoma procedures. It is a synthetic dye that assists surgeons by visually mapping lymphatic drainage pathways. The drug is administered via injection, with its primary competitors being other dyes such as methylene blue and indocyanine green.
Market Size and Demand Drivers
Market Size (2022-2023):
The global sentinel lymph node biopsy (SLNB) market was valued at approximately $1.2 billion in 2022, with a projected compound annual growth rate (CAGR) of 8-10% through 2027.
Key regions: North America accounts for 45-50% of the market, Europe 25-30%, and Asia-Pacific 15-20%.
Demand Drivers:
- Rising prevalence of breast cancer and melanoma globally.
- Increased adoption of minimally invasive surgical procedures that utilize lymphatic mapping.
- Growing awareness of sentinel lymph node biopsy as a standard of care.
- Expanding use in other oncologic surgeries, such as gynecologic cancers.
Market Share of Lymphazurin (Isosulfan Blue):
Lymphazurin holds an estimated 40-45% share of the dye market in sentinel lymph node mapping. However, this is competitive, with alternatives like methylene blue and indocyanine green constantly gaining ground.
Competitive Landscape
| Competitor |
Drugs |
Market Share (Est.) |
Status |
Notes |
| Merck & Co. |
Lymphazurin (isosulfan blue) |
~45% |
Leader in dye market |
Approved for lymphatic mapping |
| Akorn |
Methylene blue |
~35-40% |
Widely used synthetic dye |
Cost-effective alternative |
| Diagnostic Green |
Indocyanine green (ICG) |
10-15% |
Increasing use via fluorescence imaging |
Growing adoption in advanced labs |
| Others |
Patent-expired dyes |
<5% |
Niche market, experimental |
Small players, generics |
Pricing and Cost Dynamics
Current Price Range (2022-2023):
- Per 10 mL vial of Lymphazurin: $300 - $400 depending on supplier and volume.
- Cost per procedure: approximately $50 - $100, considering dosage and ancillary costs.
Price Trends:
- Prices have remained relatively stable due to existing manufacturing agreements and limited generic competition.
- Entry of biosimilar or generic ISOs may pressure prices downward after patent expiry or licensing arrangements.
Regulatory and Patent Status
- Patent Status: No active patents on Lymphazurin expired in the United States; Merck's exclusivity on formulation may have ended, opening opportunities for generics.
- FDA Status: Approved for lymphatic mapping procedures.
- Market Entry Barriers: Regulatory approval for new dye formulations or alternative agents remains substantial.
Future Price Projections and Market Trends
| Scenario |
2025 Price Estimate (per vial) |
Rationale |
Risks |
| Conservative (no new entrants) |
$350 - $400 |
Stable demand, no patent barriers, steady manufacturing costs |
Patent litigation, supply chain disruptions |
| Moderate growth (biosimilars) |
$250 - $350 |
Entry of generic versions, increased competition |
Regulatory delays, market resistance to lower-cost options |
| High competition (more substitutes) |
$200 - $300 |
Advances in imaging and dye alternatives reduce reliance on Lymphazurin |
Adoption of alternative technologies (e.g., fluorescence imaging) |
By 2025, the price per vial could decrease by approximately 20-30%, assuming the introduction of generics and increased competition.
Key Market Risks and Opportunities
Risks:
- Patent expiration potentially opening the market to generics.
- Regulatory hurdles for new dye formulations.
- Technological shifts towards fluorescence-guided lymphatic mapping reducing dependence on dyes like Lymphazurin.
Opportunities:
- Development of safer, more visible, or more cost-effective dyes.
- Expansion into emerging markets with higher cancer prevalence.
- Integration with imaging technologies such as near-infrared fluorescence for increased efficacy.
Summary
NDC 70677-1081, Lymphazurin, functions mainly as a dye in lymphatic mapping procedures. The product commands a stable price point, with potential downward pressure from generics post-2025. The overall market for lymphatic mapping agents is expanding, driven by rising cancer incidences and minimally invasive techniques. Price declines should be expected but will be influenced by patent status, technological innovation, and regional adoption rates.
Key Takeaways
- Lymphazurin holds roughly 45% of the dye market for sentinel lymph node procedures; demand linked to breast cancer and melanoma rates.
- Current vial prices hover around $350, with procedures costing $50-$100 per use.
- Market growth is steady but faces competition from newer imaging agents and alternative dyes.
- Prices may decline 20-30% by 2025, contingent on generic entry and technological shifts.
- Regulatory barriers are minimal, but patent expirations may increase generic competition.
Frequently Asked Questions
-
What factors influence the pricing of Lymphazurin?
Manufacturing costs, patent status, competition from generics, and regulatory approval influence pricing. Stable demand supports consistent prices, but patent expirations may reduce costs over time.
-
How does Lymphazurin compare to alternative dyes?
It is less expensive than often more expensive fluorescence agents like indocyanine green but offers less detailed visualization, which can influence its use depending on the procedure.
-
What is the growth outlook for lymphatic mapping dyes?
The market is projected to grow at a CAGR of 8-10% through 2027, driven by increasing cancer incidences and advances in minimally invasive procedures.
-
Are there patent restrictions affecting market entry?
Patents on specific formulation aspects may have expired, allowing for generics, but regulatory approval remains necessary for new entrants.
-
What technological trends could affect prices and usage?
The adoption of fluorescence imaging and other near-infrared techniques could reduce reliance on traditional dyes like Lymphazurin, affecting demand and pricing.
Citations
[1] MarketWatch, "Sentinel Lymph Node Biopsy Market Size," 2022.
[2] Grand View Research, "Global Lymphatic Mapping Agents Market," 2023.
[3] U.S. FDA, "Lymphazurin Approval and Regulatory Status," 2021.
[4] Reports and analyses from industry journals on dye market share and competition, 2022.
